By Dengyuemed International Business Department For decades, global oncology treatments have relied primarily on traditional modalities such as small-molecule inhibitors, antibody therapies, and cell therapies. However, challenges such as drug resistance, undruggable targets, and ...Learn More

Managing trees across residential properties, estates, or city parks requires more than handwritten notes or spreadsheets. ArboStar’s Tree Inventory and Mapping system turns complex information https://arbostar.com/arborist-software/tree-mapping into an interactive map where ...Learn More

By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More

Antibody–Drug Conjugates (ADCs): Leading the Global Oncology RevolutionAs cancer treatment enters the era of precision and personalization, Antibody–Drug Conjugates (ADCs)—often referred to as “biological missiles”—represent one of the highest frontiers of ...Learn More